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During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID
published a position paper to provide guidance for physicians involved in the care of patients with
chronic liver disease. While some healthcare systems are returning to a more normal routine, many
countries and healthcare systems have been, or still are, overwhelmed by the pandemic, which is
significantly impacting on the care of these patients. In addition, many studies have been published
focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence
the clinical course of COVID-19. While many aspects remain poorly understood, it has become
increasingly evident that pre-existing liver diseases and liver injury during the disease course must
be kept in mind when caring for patients with COVID-19. This review should serve as an update on
the previous position paper, summarising the evidence for liver disease involvement during COVID-
19 and providing recommendations on how to return to routine care wherever possible.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the
Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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for COVID-19
Patients with chronic liver diseases per se do not
appear to be over-represented in cohorts of pa-
tients with coronavirus disease 2019 (COVID-19)
where they make up less than 1% of reported
cases.1,2 These observations suggest that pa-
tients with chronic liver disease are not at
increased risk of contracting severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2).
However, the risk of infection and/or the risk of
a severe course of COVID-19 may be different
depending on the nature of the chronic liver
disease and the presence or absence of advanced
fibrosis or cirrhosis. We will therefore summa-
rise current evidence on the risk of infection and
of a severe COVID-19 course in patients with
different liver diseases.
Non-alcoholic fatty liver disease
Obesity represents a significant risk factor for a
severe course of COVID-193,4 with severe pneu-
monia being particularly increased in obese men.3
While the precise mechanisms driving this associ-
ation remain unclear, it has been postulated that
adipose tissue may serve both as a viral reservoir
and also an immunological hub for the inflamma-
tory response.5 Similarly, other elements of the
metabolic syndrome such as hypertension and
diabetes are commonly observed in patients withsevere COVID-19.6 As non-alcoholic fatty liver dis-
ease (NAFLD, or metabolic dysfunction-associated
fatty liver disease)7 and non-alcoholic steatohepa-
titis (NASH) are closely associated with these
metabolic comorbidities, identifying whether the
presence of NAFLD specifically predisposes to a
more severe course of COVID-19 is of clinical rele-
vance. A retrospective cohort of 202 patients with
COVID-19 demonstrated an association between
NAFLD and disease progression defined as deteri-
orating dyspnoea, hypoxia or radiological findings
whilst in hospital.8 This additional risk has been
observed even in younger patients with NAFLD9
and in the absence of type 2 diabetes10 and inter-
estingly, patients with NAFLD also appear to have a
longer duration of viral shedding.8 Within patients
with NAFLD, non-invasive fibrosis scores appear to
correlate with a higher likelihood of developing
severe COVID-19 illness, irrespective of metabolic
comorbidities,11 however, genetic polymorphisms
implicated in the development and progression of
NASH do not appear to be associated with severe
disease.12,13 In addition, the transcriptional activity
of genes relevant for SARS-CoV-2 infection is not
increased in liver tissues from patients with
NAFLD.14 Larger analyses are needed to determine
whether NAFLD is an independent risk factor for a
poor prognosis in COVID-19 or whether the re-
ported effects are due to the presence of con-
founding factors.medizin.uni-leipzig.de
(T. Berg).
Box 1. Open questions for liver-related basic/translational research
regarding COVID-19.
• Risk factors for increased mortality in patients after liver transplantation.
• Role of pre-existing immune activation (e.g. in cirrhosis or NAFLD/obesity) 
  in exacerbating COVID-19 outcomes.
• Identification of central hubs for SARS-CoV-2 dissemination within the 
  gastrointestinal tract and fat tissues.
• Involvement of liver endothelium in promoting SARS-CoV-2 dissemination.
• Identification of direct and indirect effects of SARS-CoV-2 on hepatocytes 
  /cholangiocytes.
• COVID-19 as a trigger for ACLF and decompensation in patients with 
  cirrhosis.
• COVID-19 induced thrombophilia as a contributor to progressive liver 
  disease.
COVID-19, coronavirus disease 2019; NAFLD, non-alcoholic fatty liver dis-
ease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
ReviewChronic viral hepatitis
In contrast to metabolic liver disease, little or no evidence has
emerged to suggest that the presence of chronic viral hepatitis
affects the COVID-19 disease course. Data from both an inter-
national registry and from a multicentre cohort study in Italy on
COVID-19 outcomes in patients with chronic liver disease
include patients with viral hepatitis (23–37%). However, despite
both studies demonstrating associations between severity of
liver disease and poor outcome, it remains unknown whether
the presence of chronic viral hepatitis influences prognosis.15,16
Autoimmune hepatitis
In the previous position paper, we advised against the with-
drawal of established immunosuppressive therapy in patients
with autoimmune liver disease17 and a panel of experts on
autoimmune liver disease have subsequently given similar rec-
ommendations.18 While there is still little evidence to demon-
strate that immunosuppressive therapy per se predisposes to
SARS-CoV-2 infection, a handful of observational studies have
suggested an association between corticosteroid use and a more
severe COVID-19 disease course.19–23 The potential implications
of these observations are discussed below in more detail. Further
data are needed to determine whether the specific risk of COVID-
19 is increased in patients with autoimmune hepatitis and the
influence of steroids and/or other immunosuppressive medica-
tions on outcome (see Box 1).
Cirrhosis
Patients with cirrhosis are at increased risk of infections and
associated complications due to cirrhosis-associated immune
dysfunction, which is particularly important for patients with
decompensated cirrhosis. A recent case series from China re-
ported that in 21 consecutive patients with pre-existing
cirrhosis, 5 did not survive SARS-CoV-2-infection24 and, specif-
ically, patients with Child-Pugh class C cirrhosis were more likely
to suffer a fatal course of COVID-19.24,25 Another case series from
Italy documented 50 patients with cirrhosis and COVID-19; 26%
of these patients presented with a model for end-stage liver
disease (MELD) score >−15, increasing from 13% at the last docu-
mented visit prior to SARS-Cov-2 infection. The 30-day mortality
was 34%, with end-stage-liver disease considered as the cause of
death in only 5 patients (29%) whilst respiratory failure due to
COVID-19 accounted for death in 12 patients (71%).15 These dataJHEP Reports 2020are in line with observations from an International registry that
reported outcomes in 103 patients with cirrhosis – nearly 40%
died, while patients with Child-Pugh class C cirrhosis were at the
highest risk of a fatal course of COVID-19 (63%, n = 27).16 Simi-
larly, multicentre hospital coding data in the USA demonstrated a
significantly higher risk of mortality from COVID-19 in patients
with chronic liver disease compared to those without, with the
highest risk found in those with cirrhosis.26 However, these data
did not have a contemporaneous comparison group of patients
with cirrhosis presenting with acute decompensation without
COVID-19. Recently, a prospective multicentre study compared
outcomes between patients with cirrhosis and COVID-19
(n = 37), cirrhosis alone (n = 127) and COVID-19 alone
(n = 108). Although rates of mortality or transfer to hospice in
patients with cirrhosis and COVID-19 were greater than in those
with COVID-19 alone (30% vs. 13%, p = 0.03) there was no sig-
nificant difference compared to those with cirrhosis alone (30%
vs. 20%; p = 0.11). The presence of acute-on-chronic liver failure
(ACLF) was also similar in the 2 cirrhosis groups (29.7% vs. 22.8%)
as was mortality in patients with ACLF (55% vs. 36%; p = 0.25)
although the number of cases was small.27 Taken together, we
cannot currently conclude that COVID-19 increases the risk of
ACLF or mortality in patients with cirrhosis more than other
causes of decompensation. However, in patients with COVID-19,
mortality is markedly greater in those with cirrhosis than in
those without cirrhosis.
Liver transplantation recipients
The clinical course of COVID-19 in immunosuppressed transplant
recipients may differ from that in non-immunosuppressed pa-
tients.28 Indeed, while hepatocellular injury, as characterised by
elevated serum aminotransferases, appears to be relatively less
prevalent, acute kidney injury is more common in transplant
recipients with COVID-19, possibly due to the use of calcineurin
inhibitors.28 These findings will need confirmation in larger case
series; however, in line with the general risk factors for severe
COVID-19, elderly patients with comorbidities are among those
with the highest risk within the cohort of transplant re-
cipients.28,29 Early reports from Italy described low mortality
rates in transplant recipients <5%,20,30 however subsequent an-
alyses have reported mortality rates in liver and other solid or-
gan transplant recipients at around 25%.28,31–34 The results of a
prospective European study from 19 transplant centres were
recently reported,35 including 57 liver transplant (LT) recipients
with confirmed SARS-CoV-2 infection. Overall and in-hospital
case-fatality rates were 12% and 17%, respectively, which are
similar to the expected mortality for patients with severe COVID-
19 infection. Five of the 7 patients who died had an underlying
history of cancer. Taken together the currently available data do
not support the notion that transplantation or specific immu-
nosuppressive regimens significantly affect the risk of a severe
disease course, but those with underlying cancer may require
special attention.28,31,35
Liver injury secondary to COVID-19
Deranged liver biochemistry of varying degrees is common in pa-
tients with COVID-19, having been reported in 19–76% of
cases.36–41 Most of these studies report a predominantly hepato-
cellular pattern of liver injury with elevated serum aminotrans-
ferases (rarely >5 × the upper limit of normal) although cholestatic
or mixed patterns of liver injury have also been reported.2vol. 2 j 100169
Importantly, this appears to occur to a similar degree in patients
with and without pre-existing liver disease26 and has also been
documented in pregnant women in association with increased
levels of pro-inflammatory cytokines.42 To what extent this liver
injury isderived fromthedirecteffectof SARS-CoV-2, asopposed to
a secondary phenomenon caused by the broader COVID-19 disease
course remains to be elucidated. SARS-CoV-2 infection of hepato-
cytes with subsequent mitochondrial disturbance and apoptosis
has been suggested,41 but requires confirmatory testing, particu-
larly since single cell RNA sequencing has shown relatively sparse
hepatocyte expressionof the receptorsnecessary for viral uptake.43
Similarly, direct infection of cholangiocytes via angiotensin-
converting enzyme 2 (ACE2) has been posited as a potential
mechanism for intrinsic liver injury,44 but requires further inves-
tigation. Given the profound multi-systemic involvement of
COVID-19, particularly in the severe and critical forms of disease,
liver injury is likely to be multifactorial with contributions from
systemic inflammation, intrahepatic immune activation, micro-
vascular thrombosis, hepatic congestion, perturbations of the gut-
liver-axis, as well as drug toxicity.45–48 The prognostic significance
of deranged biochemistry in COVID-19 remains unresolved49;
somegroupshavedemonstrated a strong correlationwithduration
of hospitalisation, organ failure and intensive care unit admis-
sion37,41,50 whilst others have failed to observe any significant as-
sociations with outcome.39,40Recommendations for the management of patients
with chronic liver disease
General recommendations
In the aftermath of the COVID-19 peak, there was an urgent need
to anticipate and plan for the wave of liver disease yet to come.
This will be characterised by emergent hepatic decompensation,Alterations to
standard of care
Progression of
liver disease
Resumption of
targeted treatment
& surveillance
Patient
education &
intensive lifestyle
advice
Recommen
Fig. 1. Liver disease progression and poor outcomes from severe acute respir
therefore be a concerted effort to resume standard of care and restore hepatolog
JHEP Reports 2020increased dropouts from transplant waiting lists and a vast back-
log of deferred hospital visits and testing.51 Clinicians and their
institutions should therefore be proactive in structuring their
services to tackle these challenges and strive to resume standard
of care for patients with liver disease wherever possible. Equally,
it is important to embrace innovative technologies and methods
of practice developed during the pandemic which may continue
to be of benefit to patients (e.g. telemedicine use, remote moni-
toring).52 Combining standard of care with novel ideas will help
to mitigate against longer term consequences of the pandemic
including missed diagnoses, incomplete hepatocellular carcinoma
(HCC) screening, and progressive liver disease. Furthermore, in
light of accumulating evidence that baseline liver disease severity
is associated with poor outcomes from COVID-19,15,16 treatment
of underlying liver disease may represent one of the most
important strategies to protect patients from the adverse effects
of any future SARS-CoV-2 infection. This in turn will further
reduce the burden on healthcare systems and allow more rapid
return towards gold standard hepatology practice (Fig. 1). The
epidemiology of COVID-19 has proven unpredictable, but the
burden of disease is likely to expand and shrink episodically
within populations for some time to come. The approach to pa-
tient care must therefore be personalised and flexible, balancing
national dynamics of SARS-CoV-2 infection, the local resource
availability, and the type and severity of each individual patient’s
underlying liver disease (Fig. 2). Lastly, with time, it will be
important to resume clinical trial enrolment wherever possible to
allow the field to advance despite unprecedented global events.Specific recommendations
NAFLD
 Patients should be made aware of potential adverse meta-
bolic and hepatic consequences of social isolation, includingStrain on healthcare 
services
Early admission,
testing &
treatment of
high-risk groups
Resumption of
liver
transplantation
dations
Hospitalisation &
severe COVID-19
atory syndrome coronavirus 2 infection are closely associated. There must
y/transplantation services in order to improve patient outcomes.
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All patients with chronic liver disease should adhere to common rules of physical distancing
Non-alcoholic fatty liver disease 
• Patients should be made aware of potential 
adverse metabolic and hepatic consequences 
of social isolation, including more sedentary 
lifestyles and increased consumption of 
processed foods. 
Preventing liver disease progression through 
intensive lifestyle intervention, including 
nutritional guidance, weight loss advice, and 
diabetes management may help prevent the 
development of a severe disease course with 
future SARS-CoV-2 infection. 
Treatment of arterial hypertension should 
continue in accordance with existing 
guidelines. There is currently no evidence 
showing that angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers 
increase the risk of SARS-CoV-2 infection or 
the risk of developing severe complications or 
death from COVID-19. 
Early admission should be considered for all 
patients with NAFLD who become infected with 
SARS-CoV-2.
•
•
•
Autoimmune liver disease  
 • In patients with autoimmune liver disease, we 
currently advise against reducing 
immunosuppressive therapy to prevent 
SARS-CoV-2 infection. Reductions should only 
be considered under special circumstances 
(e.g. medication-induced lymphopenia, or 
bacterial/fungal superinfection in cases of 
severe COVID-19) after consultation with a 
specialist.
Whilst corticosteroid treatment has shown 
promise for hospitalised patients with 
COVID-19 requiring respiratory support, 
concerns remain that patients who are already 
taking higher doses of corticosteroids may be 
more susceptible to SARS-CoV-2 infection and 
severe COVID-19. To minimise systemic 
glucocorticoid exposure we therefore 
recommend considering budesonide as a 
first-line agent to induce remission in patients 
without cirrhosis who have a flare of 
autoimmune hepatitis.
In patients treated with corticosteroids who 
develop COVID-19, corticosteroid dosing 
should be sufficient to prevent adrenal 
insufficiency. Addition of, or conversion to, 
dexamethasone should only be considered in 
patients with COVID-19 who require 
hospitalisation and respiratory support. 
There remains a paucity of data to make 
specific recommendations for patients with 
primary biliary cholangitis, primary sclerosing 
cholangitis or IgG4-related disease. 
All patients should receive vaccination for 
Streptococcus pneumoniae and influenza.
•
•
•
•
Alcohol-related liver disease
•  Chronic alcohol consumption may increase an
individual's susceptibility to acute respiratory 
distress syndrome secondary to SARS-CoV-2 
infection.
Social isolation can lead to new or increased 
alcohol consumption; an increase in alcohol-
related admissions including new hepatic 
decompensation should be anticipated during 
and after periods of physical distancing. 
Clinicians and institutions should therefore 
implement pre-emptive strategies such as 
patient outreach and telephone alcohol liaison 
and cessation services. 
Whilst corticosteroid treatment has shown 
promise for hospitalised patients with 
COVID-19 requiring respiratory support, 
concerns remain that patients who are already 
taking higher doses of corticosteroids may be 
more susceptible to severe COVID-19. These 
concerns must be considered when initiating 
corticosteroids as a treatment for patients with 
severe alcoholic hepatitis. 
Clinicians should be aware of misinformation 
circulating online regarding the protective 
effects of alcohol against SARS-CoV-2, 
leading to previous instances of deliberate 
excess consumption. 
•
•
•
•
Viral hepatitis 
• Continue treatment of chronic HCV and chronic 
HBV if already receiving treatment. 
Use telemedicine/local laboratory testing for 
follow-up visits in patients receiving antiviral 
therapy, send follow-up prescriptions by mail 
and supply extended prescription supplies 
including full courses of direct-acting antiviral 
medications to complete HCV treatment if this 
has been initiated. However, patients with poor 
compliance with medications should be 
considered for directly observed treatment 
protocols.
In patients without COVID-19, treatment for 
HCV and HBV should be initiated according to 
general guidelines.
Given the unknown impact of interferon alpha 
on systemic inflammation associated with 
COVID-19, alternative agents should be 
considered when initiating treatment for 
patients with HBV during the COVID-19 
pandemic. 
In patients with COVID-19, initiation of 
treatment for HBV and HCV is usually not 
warranted and should be deferred until 
recovery from COVID-19.
In patients with COVID-19 in whom there is 
evidence of high disease activity (flare) or 
clinical suspicion for severe acute HBV 
hepatitis, a decision to initiate antiviral therapy 
should be made on a case-by-case basis in 
consultation with a specialist. 
In patients with chronic, occult or resolved HBV 
and COVID-19 receiving corticosteroids, 
tocilizumab or other immunosuppressive 
agents, consider the use of antiviral therapy to 
prevent viral flare or reactivation.
Continue to work towards the World Health 
Organization goal of eliminating viral hepatitis 
by 2030 by trying to adapt the cascade-of-care 
to the new coronavirus situation and make 
modifications for safe delivery of services 
according to local requirements.
•
•
•
•
•
•
•
Hepatocellular carcinoma  
 • The specific risk of COVID-19 in patients with 
HCC remains undefined.
However, mortality from COVID-19 in patients 
with cancer appears to be determined by age, 
sex, and comorbidities as opposed to the use of 
cytotoxic chemotherapy or other anticancer 
treatment.
Care should be maintained according to 
guidelines including continuing systemic 
treatments and evaluation for LT. 
Multidisciplinary HCC boards should continue 
to function remotely and provide treatment 
recommendations
Full HCC surveillance should resume where 
possible. Where resources remain limited, 
patients at increased risk, such as those with 
elevated alpha-fetoprotein levels, advanced 
cirrhosis, chronic hepatitis B, NASH/diabetes 
etc. should be prioritised in conjunction with the 
use of published HCC risk stratification scores.
•
•
•
•
Liver transplant recipients  
•
•
•
•
•
We advise against reduction of immunosup-
pressive therapy to prevent SARS-CoV-2 
infection. Reduction should only be considered 
under special circumstances (e.g. medication-
induced lymphopenia, or bacterial/fungal 
superinfection in case of severe COVID-19) 
after consultation with a specialist.
Clinicians must be aware of the high reported 
rates of fear and anxiety regarding COVID-19 
in LT recipients and the barrier this may pose 
to compliance with immunosuppressive 
medication and attendance at scheduled 
medical visits.
Drug levels of calcineurin inhibitors and 
mechanistic target of rapamycin inhibitors 
should be closely monitored when they are 
administered together with drugs such as 
hydroxychloroquine, protease inhibitors or 
alongside new trial drugs for COVID-19. Early 
admission should be considered for all LT 
recipients who develop COVID-19. 
Risk factors for a severe course of COVID-19 
in LT recipients may include underlying 
malignancy, sarcopenia, graft dysfunction and 
metabolic comorbidities. However, the 
individual contributions of these factors require 
further clarification.
All patients should receive vaccination for 
Streptococcus pneumoniae and influenza
Cirrhosis
Patients with cirrhosis are particularly 
vulnerable to both the consequences of 
SARS-CoV-2 infection and to the adverse 
effects of delayed or altered standard of care 
during the COVID-19 pandemic.
Every effort should be made to resume the 
best standard of care for patients with 
cirrhosis according to guidelines wherever 
possible.
Patients with cirrhosis who are infected with 
SARS-CoV-2 are at high risk of new or 
worsening hepatic decompensation, severe 
COVID-19 and death.
All patients with new or worsening hepatic 
decompensation or ACLF should be 
prioritised for SARS-CoV-2 testing even in the 
absence of respiratory symptoms.
In those with cirrhosis who are admitted for 
reasons other than COVID-19, particular effort 
should be made to manage these patients in 
a designated non-COVID-19 ward. 
Guidelines on prophylaxis of spontaneous 
bacterial peritonitis, gastrointestinal 
haemorrhage, and hepatic encephalopathy 
should be closely followed to prevent 
decompensation and avoid admission. Early 
admission should be considered for all 
patients with cirrhosis who become infected 
with SARS-CoV-2.
Because of the potential of circulatory 
dysfunction, the use of vasoconstrictor 
therapy, which is known to increase 
pulmonary pressure and decrease cardiac 
output, should be considered with great 
caution among critically ill patients with 
cirrhosis and COVID-19.
Rapid clinical deterioration in patients with 
advanced liver disease and COVID-19 should 
prompt consideration of a symptoms-based 
approach using palliative care guidelines. All 
patients should receive vaccination for 
Streptococcus pneumoniae and influenza
•
•
•
•
•
•
•
•
Liver transplant candidates
• Patients on the LT waiting list with
decompensated cirrhosis are at high risk of 
severe COVID-19 and death following 
SARS-CoV-2 infection. 
We therefore recommend that LT centres aim 
to restore transplantation services following the 
peak of the COVID-19 epidemic wherever 
possible. 
In centres with ongoing resource limitations, LT 
should be prioritised for patients with poor 
short-term prognosis including those with acute 
liver failure, ACLF, high MELD score (including 
exceptional MELD points) and HCC at the 
upper limits of the Milan criteria.
The risk of SARS-CoV-2 transmission via LT 
remains unknown; therefore, we currently 
recommend testing all donors for SARS-CoV-2 
infection by reverse transcription PCR and 
recommend against using livers from 
SARS-CoV-2-infected donors. 
We encourage LT centres to develop and 
improve local and global risk stratification 
pathways for LT donors and recipients, 
incorporating a combination of clinical history, 
chest radiology, and SARS-CoV-2 testing, as 
well as ethical considerations regarding 
transplantation activities and allocation. 
Measures should be taken to reduce the risk of 
SARS-CoV-2 infection in the peri-transplanta-
tion period. In areas of high disease burden, a 
COVID-19 free pathway through transplantation 
should be implemented, including strict social 
isolation for waiting list patients, telephone 
screening for symptoms and exposures before 
admission, and perioperative management in a 
designated clean intensive care unit and post-
LT ward. 
Consent for diagnostic and therapeutic 
procedures related to transplantation should 
include the potential risk of nosocomial 
COVID-19.
LT candidates should be made aware that 
infection with SARS-CoV-2 in patients 
undergoing major surgery is associated with an 
increased risk of severe COVID-19 and death. 
Living-donor transplantations should be 
considered on a case-by-case basis and 
include careful risk stratification of donor and 
recipient, incorporating a combination of clinical 
history, chest radiology, and 
SARS-CoV-2 testing.
•
•
•
•
•
•
•
•
Fig. 2. Summary of recommendations. ACLF, acute-on-chronic liver failure; COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; LT, liver
transplant; MELD, model for end-stage liver disease; NASH, non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Reviewmore sedentary lifestyles and increased consumption of
processed foods.
 Preventing liver disease progression through intensive life-
style intervention, including nutritional guidance, weight
loss advice, and diabetes management may help prevent theJHEP Reports 2020development of a severe disease course with future SARS-
CoV-2 infection.
 Treatment of arterial hypertension should continue in
accordance with existing guidelines. There is currently no
evidence showing that angiotensin-converting enzyme4vol. 2 j 100169
inhibitors or angiotensin receptor blockers increase the risk
of SARS-CoV-2 infection or the risk of developing severe
complications or death from COVID-19.53
 Early admission should be considered for all patients with
NAFLD who become infected with SARS-CoV-2.Viral hepatitis
 Continue treatment of chronic HCV and chronic HBV if
already receiving treatment.
 Use telemedicine/local laboratory testing for follow-up visits
in patients receiving antiviral therapy, send follow-up pre-
scriptions by mail and supply extended prescription supplies
including full courses of direct-acting antiviral medications
to complete HCV treatment if this has been initiated. How-
ever, patients with poor compliance with medications
should be considered for directly observed treatment
protocols.
 In patients without COVID-19, treatment for HCV and HBV
should be initiated according to general guidelines.54,55
 Given the unknown impact of interferon alpha on systemic
inflammation associated with COVID-19, alternative agents
should be considered when initiating treatment for patients
with HBV during the COVID-19 pandemic.
 In patients with COVID-19, initiation of treatment for HBV
and HCV is usually not warranted and should be deferred
until recovery from COVID-19.
 In patients with COVID-19 in whom there is evidence of high
disease activity (flare) or clinical suspicion for severe acute
HBV hepatitis, a decision to initiate antiviral therapy should
be made on a case-by-case basis in consultation with a
specialist.
 In patients with chronic, occult or resolved HBV and COVID-
19 receiving corticosteroids, tocilizumab or other immuno-
suppressive agents, consider the use of antiviral therapy to
prevent viral flare or reactivation.
 Continue to work towards the World Health Organization
goal of eliminating viral hepatitis by 2030 by trying to adapt
the cascade-of-care to the new coronavirus situation and
make modifications for safe delivery of services according to
local requirements.Alcohol-related liver disease
 Chronic alcohol consumption may increase an individual’s
susceptibility to acute respiratory distress syndrome sec-
ondary to SARS-CoV-2 infection.56
 Social isolation can lead to new or increased alcohol con-
sumption57; an increase in alcohol-related admissions
including new hepatic decompensation should be antici-
pated during and after periods of physical distancing.
 Clinicians and institutions should therefore implement pre-
emptive strategies such as patient outreach and telephone
alcohol liaison and cessation services.
 Whilst corticosteroid treatment has shown promise for
hospitalised patients with COVID-19 requiring respiratory
support,58 concerns remain that patients who are already
taking higher doses of corticosteroids may be more suscep-
tible to severe COVID-19.19,59 These concerns must be
considered when initiating corticosteroids as a treatment for
patients with severe alcoholic hepatitis.JHEP Reports 2020 Clinicians should be aware of misinformation circulating
online regarding the protective effects of alcohol against
SARS-CoV-2, leading to previous instances of deliberate
excess consumption.60Autoimmune liver disease
 In patients with autoimmune liver disease, we currently
advise against reducing immunosuppressive therapy to
prevent SARS-CoV-2 infection. Reductions should only be
considered under special circumstances (e.g. medication-
induced lymphopenia, or bacterial/fungal superinfection in
cases of severe COVID-19) after consultation with a specialist.
 Whilst corticosteroid treatment has shown promise for
hospitalised patients with COVID-19 requiring respiratory
support,58 concerns remain that patients who are already
taking higher doses of corticosteroids may be more suscep-
tible to SARS-CoV-2 infection and severe COVID-19.19,59 To
minimise systemic glucocorticoid exposure we therefore
recommend considering budesonide as a first-line agent to
induce remission in patients without cirrhosis who have a
flare of autoimmune hepatitis.61
 In patients treated with corticosteroids who develop COVID-
19, corticosteroid dosing should be sufficient to prevent
adrenal insufficiency. Addition of, or conversion to, dexa-
methasone should only be considered inpatientswith COVID-
19 who require hospitalisation and respiratory support.58
 There remains a paucity of data to make specific recom-
mendations for patients with primary biliary cholangitis,
primary sclerosing cholangitis or IgG4-related disease.
 All patients should receive vaccination for Streptococcus
pneumoniae and influenza.Cirrhosis
 Patients with cirrhosis are particularly vulnerable to both the
consequences of SARS-CoV-2 infection and to the adverse
effects of delayed or altered standard of care during the
COVID-19 pandemic.
 Every effort should be made to resume the best standard of
care for patients with cirrhosis according to guidelines62
wherever possible.
 Patients with cirrhosis who are infected with SARS-CoV-2
are at high risk of new or worsening hepatic decompensa-
tion, severe COVID-19 and death.15,16
 All patients with new or worsening hepatic decompensation
or ACLF should be prioritised for SARS-CoV-2 testing even in
the absence of respiratory symptoms.16
 In those with cirrhosis who are admitted for reasons other
than COVID-19, particular effort should be made to manage
these patients in a designated non-COVID-19 ward, prefer-
ably in a side-room, in order to reduce the risk of nosocomial
SARS-CoV-2 infection.
 Guidelines on prophylaxis of spontaneous bacterial perito-
nitis, gastrointestinal haemorrhage, and hepatic encephalop-
athy should be closely followed to prevent decompensation
and avoid admission.62
 Early admission should be considered for all patients with
cirrhosis who become infected with SARS-CoV-2.
 Because of the link between COVID-19 and circulatory
dysfunction, in particular of the pulmonary circulation,63 the5vol. 2 j 100169
Reviewuse of vasoconstrictor therapy, which is known to increase
pulmonary pressure and decrease cardiac output, should be
considered with great caution among critically ill patients
with cirrhosis and COVID-19.
 Rapid clinical deterioration in patients with advanced liver
disease and COVID-19 should prompt consideration of a
symptoms-based approach using palliative care guidelines.64
 All patients should receive vaccination for Streptococcus
pneumoniae and influenza.Liver transplant candidates
 Patients on the LT waiting list with decompensated cirrhosis
are at high risk of severe COVID-19 and death following
SARS-CoV-2 infection.
 We therefore recommend that LT centres aim to restore
transplantation services following the peak of the COVID-19
epidemic wherever possible.
 In centres with ongoing resource limitations, LT should be
prioritised for patients with poor short-term prognosis
including those with acute liver failure, ACLF, high MELD
score (including exceptional MELD points) and HCC at the
upper limits of the Milan criteria.
 The risk of SARS-CoV-2 transmission via LT remains un-
known65; therefore, we currently recommend testing all
donors for SARS-CoV-2 infection by reverse transcription
PCR and recommend against using livers from SARS-CoV-2-
infected donors.66
 We encourage LT centres to develop and improve local and
global risk stratification pathways for LT donors and re-
cipients, incorporating a combination of clinical history,
chest radiology, and SARS-CoV-2 testing,67 as well as ethical
considerations regarding transplantation activities and
allocation.68
 Measures should be taken to reduce the risk of SARS-CoV-2
infection in the peri-transplantation period. In areas of
high disease burden, a COVID-19 free pathway through
transplantation should be implemented, including strict so-
cial isolation for waiting list patients, telephone screening for
symptoms and exposures before admission, and periopera-
tive management in a designated clean intensive care unit
and post-LT ward.69
 Consent for diagnostic and therapeutic procedures related to
transplantation should include the potential risk of nosoco-
mial COVID-19.
 LT candidates should be made aware that infection with
SARS-CoV-2 in patients undergoing major surgery is associ-
ated with an increased risk of severe COVID-19 and death.70
 Living-donor transplantations should be considered on a
case-by-case basis and include careful risk stratification of
donor and recipient, incorporating a combination of clinical
history, chest radiology, and SARS-CoV-2 testing.Liver transplant recipients
 We advise against reduction of immunosuppressive therapy
to prevent SARS-CoV-2 infection. Reduction should only be
considered under special circumstances (e.g. medication-
induced lymphopenia, or bacterial/fungal superinfection in
case of severe COVID-19) after consultation with a specialist.
 Clinicians must be aware of the high reported rates of fear
and anxiety regarding COVID-19 in LT recipients and theJHEP Reports 2020barrier this may pose to compliance with immunosuppres-
sive medication and attendance at scheduled medical
visits.71
 Drug levels of calcineurin inhibitors and mechanistic target
of rapamycin inhibitors should be closely monitored when
they are administered together with drugs such as hydrox-
ychloroquine, protease inhibitors or alongside new trial
drugs for COVID-19.
 Early admission should be considered for all LT recipients
who develop COVID-19.
 Risk factors for a severe course of COVID-19 in LT recipients
may include underlying malignancy, sarcopenia, graft
dysfunction and metabolic comorbidities. However, the in-
dividual contributions of these factors require further
clarification.
 All patients should receive vaccination for Streptococcus
pneumoniae and influenza.Hepatocellular carcinoma
 The specific risk of COVID-19 in patients with HCC remains
undefined.
 However, mortality from COVID-19 in patients with cancer
appears to be determined by age, sex, and comorbidities as
opposed to the use of cytotoxic chemotherapy or other
anticancer treatment.72
 Care should be maintained according to guidelines including
continuing systemic treatments and evaluation for LT.
 Multidisciplinary HCC boards should continue to function
remotely and provide treatment recommendations.
 Full HCC surveillance should resume where possible. Where
resources remain limited, patients at increased risk, such as
those with elevated alpha-fetoprotein levels, advanced
cirrhosis, chronic hepatitis B, NASH/diabetes etc. should be
prioritised in conjunction with the use of published HCC risk
stratification scores.Liver-related diagnostic procedures
Endoscopy
Endoscopic procedures are associated with an increased risk of
disseminating SARS-CoV-2. During oesophagogastroduodeno-
scopy (OGD) or endoscopic retrograde cholangiography (ERC),
spreading of virus-containing droplets can occur. In addition,
shedding of the virus in the faeces increases the risk of
dissemination during colonoscopy. Thus, depending on the local
COVID-19 burden, we recommend SARS-CoV-2 testing prior to
endoscopic procedures in all patients. In patients who test
negative and in areas with low COVID-19 burden, OGD (to screen
for and treat varices) and ERC (for duct dilatation or stent
replacement in patients after LT or patients with primary scle-
rosing cholangitis) should not be delayed.
In patients with COVID-19, indications for endoscopic pro-
cedures should be limited to emergencies such as gastrointes-
tinal bleeding and bacterial cholangitis.
Ultrasound (HCC surveillance)
HCC surveillance should only be deferred based on available
resources (including availability of therapeutic options in case of
HCC diagnosis) at the centre and the individual risk assessment.
Patients with increased risk (e.g. patients with elevated alpha-6vol. 2 j 100169
fetoprotein levels, advanced cirrhosis, chronic hepatitis B, HCV-
related cirrhosis [even after cure], NASH/diabetes) should be
prioritised if resources are limited.
In patients with COVID-19, HCC surveillance can be deferred
until after recovery.
Liver biopsy
In areas with low COVID-19 burden, liver biopsies should be
performed as indicated, including grading/staging for NAFLD and
chronic viral hepatitis and histological assessment of elevated
transaminases of unknown aetiology. In areas with high COVID-
19 burden or limited availability of resources, biopsy should be
prioritised in patients with severely elevated transaminases of
unclear cause (e.g. alanine aminotransferase >5× upper limit of
normal), suspected transplant rejection and liver masses suspi-
cious of malignancy.
In patients with COVID-19, liver biopsy may be performed
based on the individual indication for histological assessment. It
must be considered that treatment/care for COVID-19 may
outweigh the diagnosis of co-existing liver disease and that
systemic inflammation associated with COVID-19 is likely to
obscure aetiology-specific histologic characteristics. As discussed
earlier, liver function test abnormalities are common in patients
with COVID-19, particularly in those with more severe disease,
and routine liver biopsy is not required in this context.Liver-specific considerations in the pharmacological
management of COVID-19
The targeted management of COVID-19 is a rapidly evolving field
with a plethora of new or repurposed medications constantly
shifting in and out of favour. In Europe alone there are currently
over 200 registered COVID-19 specific drug trials.73 This number
will no doubt continue to increase as we learn more about the
pathophysiology of the disease. It is beyond the scope of this
updated position paper to comprehensively review the potential
therapeutic options for COVID-19. While some interventions,
such as infusion of convalescent plasma or favipiravir (recently
approved in India) show encouraging signals of efficacy, little is
known about their liver-specific side effects or contraindications.
However, for some therapeutic agents there are liver-specific
considerations which we will discuss. Hepatologists must be
mindful of the secondary effects these drugs may have on the
liver and continually evaluate the specific risks and benefits
conferred to their patients with underlying liver disease.
Remdesivir
Remdesivir is an adenosine-analogue that induces RNA chain
termination and was initially developed as an antiviral agent
against Ebola. It has emerged as a promising treatment candidate
against COVID-19, having been shown to reduce the duration of
symptoms when used early in the disease course.74,75 Despite
preclinical investigations demonstrating reversible aminotrans-
ferase elevations,76 use of remdesivir in controlled trials has not
demonstrated a significant impact on liver function tests
compared with placebo. In the largest randomised control trial to
date, Beigel et al. observed no difference in the rate of amino-
transferase elevation between patients taking remdesivir
compared with placebo (4% vs. 5.9%).74 Similarly, Wang et al. also
reported comparable rates of transaminase elevation in patients
receiving remdesivir or placebo.77 Both trials excluded patients
with baseline alanine or aspartate aminotransferase >5× upperJHEP Reports 2020limit of normal and Wang et al. also excluded patients with
cirrhosis. Should remdesivir ultimately move into mainstream
use, caution should therefore be exercised in patients with
advanced liver disease or with severe baseline derangements in
liver biochemistry, but otherwise transaminase elevations do not
appear to occur over and above what may be expected as part of
the typical disease course of COVID-19. Remdesivir is approved
for the treatment of COVID-19 in several European countries.
Tocilizumab
Interleukin-6 (IL-6) appears to be a key driver of the “cytokine
storm” leading to significant lung and other organ damage in
cases of severe COVID-19. Tocilizumab, a humanised monoclonal
antibody targeting IL-6 has therefore been postulated to counter
this dysregulated inflammation and has shown promise in
retrospective series of COVID-19 by reducing the need for, and
duration of, organ support.78 The liver-specific side effect profile
of tocilizumab is well established due to its widespread use in
rheumatoid arthritis and other auto-inflammatory conditions.
Mild serum aminotransferase elevations are common and are
usually self-limiting and asymptomatic,79 however, progressive
jaundice requiring LT has been reported.80 Rarely, tocilizumab
has been associated with HBV reactivation81 and therefore HBV
serology should form part of routine pre-treatment work-up.
Corticosteroids
There seems to be a dichotomous relationship between corti-
costeroids and COVID-19. Whilst patients already taking corti-
costeroids may be at increased risk of adverse outcomes from
COVID-19, those with established severe disease seem to para-
doxically benefit from corticosteroid introduction. In patients
with inflammatory bowel disease, the use of corticosteroids has
been associated with intensive care unit admission, ventilator
requirement and/or death.19 Similarly, patients on maintenance
glucocorticoids for rheumatological conditions have an increased
rate of hospitalisation following SARS-CoV-2 infection.59 As yet,
small case series have been unable to draw definitive conclusions
regarding the risks posed by corticosteroid use in patients with
autoimmune hepatitis or after LT.31,34 In these patients, the risks
of hepatitis flares or graft rejection must be weighed against the
potential risks of developing severe COVID-19. Currently, we
advise against routine reduction of immunosuppression in pa-
tients with autoimmune hepatitis or LT recipients, including the
use of steroids if required. Corticosteroids however do appear to
be a viable treatment option for patients with severe COVID-19
requiring respiratory support. In June 2020, the RECOVERY58
trial reported that dexamethasone reduced deaths by one-third
in ventilated patients and by one-fifth in patients receiving
supplemental oxygen. It is likely that this agent will be increas-
ingly used in the management of severe COVID-19 including in
patients with pre-existing chronic liver disease.
Anticoagulation
Patients with advanced liver disease are at increased risk of
venous thromboembolism.82 Similarly, coagulopathy is a com-
mon abnormality in patients with COVID-19 and has emerged as
a major driver of morbidity and mortality, particularly in patients
with severe disease. Hospitalised patients with COVID-19 have
alarmingly high rates of venous thromboembolic disease with an
observed incidence of 20% at day 7, and 42% at day 21 despite
thromboprophylaxis.83 As well as macro-thrombotic events,
COVID-19 is also associated with widespread micro-thrombosis7vol. 2 j 100169
Reviewand endothelial dysfunction contributing to multiorgan failure in
the terminal phase of the disease.84,85 The role of anticoagulation
in patients with COVID-19 has therefore been extensively
investigated and has been shown to improve outcomes in severe
COVID-19,86 although unified risk stratification models and
treatment thresholds have yet to emerge. Given that both
advanced liver disease and COVID-19 are both associated with a
hypercoagulable state, it reasons that SARS-CoV-2 infection in
patients with cirrhosis may yield a cumulative risk of pro-
thrombotic complications. We therefore suggest that in this
scenario patients should be deemed at particularly high risk of
thromboembolic events. Whilst historically there have been
reservations about the use of anticoagulation in patients with
cirrhosis and portal hypertension, systematic review hasJHEP Reports 2020demonstrated no excess of bleeding events in anticoagulated
patients with cirrhosis and portal vein thrombosis.87 Further-
more, anticoagulation may have antifibrotic properties88 and
even confer a survival advantage in patients with cirrhosis.89
Further reassurance is provided by a recent multicentre Italian
study in which 80% of patients with cirrhosis and COVID-19
received thromboprophylaxis without any evidence of major
haemorrhagic complications.15 Whilst thromboprophylaxis,
typically with low molecular weight heparin, should form part of
standard of care for all patients with cirrhosis admitted to hos-
pital, it remains to be determined whether patients with COVID-
19 and cirrhosis should receive early treatment with enhanced or
therapeutic anticoagulation.Abbreviations
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